Opendata, web and dolomites

CG-100

A next generation medical device that enhances patient care and treatment following colorectal surgery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CG-100 project word cloud

Explore the words cloud of the CG-100 project. It provides you a very rough idea of what is the project "CG-100" about.

company    2010    pains    stage    complications    device    doctors    patient    leaks    headquartered    bag    causing    healthcare    full    moving    advisors    colonic    al    leads    confidently    employees    threatening    improves    life    clinical    contact    skin    ltd    vast    team    procedure    infections    depression    bypass    colorectal    bags    time    diseases    anastomosis    intraluminal    active    functions    complication    care    cologuard    prevent    2014    multiple    faecal    proprietary    cg    solution    ostomy    50    israel    waste    cancer    quality    parastomal    entrepreneurs    subcontractors    mark    trials    sepsis    place    risky    talks    surgeons    silicon    marketing    dec    single    external    chronic    economic    shown    companies    founded    internal    healing    received    ulcers    employ    site    date    stoma    profound    medical    hernia    surgery    ce    comprising    reducing    stomas    diverting    eur    patients    anastomotic    content    leakage   

Project "CG-100" data sheet

The following table provides information about the project.

Coordinator
COLOSPAN LTD 

Organization address
address: 21 ATIR YEDA STREET
city: KFAR SABA
postcode: 4464316
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.cologuard.co.il
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COLOSPAN LTD IL (KFAR SABA) coordinator 50˙000.00

Map

 Project objective

Cologuard Ltd is a clinical stage medical device company founded in Dec 2010. Cologuard's novel and proprietary technology for colorectal surgery was developed in order to prevent the profound clinical and economic pains associated with anastomotic leaks and diverting colonic stomas. Anastomotic leakage (AL) is a life threatening complication, which can occur following colorectal surgery for colorectal cancer or other diseases. In order to prevent AL, surgeons use a procedure called diverting stoma, which result in an ostomy bag for external bypass of waste. This solution leads to a low quality of life for patients, causing many clinical complications, including sepsis, parastomal hernia, ulcers, chronic depression and skin infections. In addition, this procedure has a high economic cost for the patient and the healthcare system. The Cologuard team have developed the CG-100, a single use intraluminal device composed of silicon, which functions as an internal bypass for colonic content, reducing contact between faecal content and the anastomosis site. The device allows healing to take place without the need for an external diverting stoma and ostomy bag. The CG-100 device improves patient care through the reduction of risky complications associated with ostomy bags, improving the healing process and providing a better quality of life. Healthcare costs will be greatly reduced by up to 50%. The company is composed of a strong team comprising top doctors and medical advisors as well as entrepreneurs with vast experience in the medical device sector. The company received CE mark for its lead product in 2014 and is confidently moving towards pre-marketing clinical trials in the EU. Cologuard has received over 4.2 M EUR funding to date. The company is headquartered in Israel and employ 5 full time employees and multiple subcontractors. The company is currently in talks with companies in the EU who have shown an active interest in the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CG-100" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CG-100" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More